SCHEMBL342143

SCHEMBL342143

O=C1C2=CC=CCC2=COc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 2/20 0.33
MIF P14174 1/20 0.33
MAOB P27338 3/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
TP53 P04637 1/20 0.31
HPGD P15428 1/20 0.31
STK17B O94768 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL343376 0.93 PKM (0.34) PKMTSHRMAPTMAOBKDM4E
SCHEMBL11634662 0.81 KDM4E (0.33) MAOBKDM4ESTK17B
SCHEMBL3707104 0.73 CDC25B (0.41) PKMMAPTMAOBKDM4ELMNA
SCHEMBL989080 0.73 BACE1 (0.47) PKMMAPTMAOBLMNATP53
SCHEMBL10566394 0.72 MAOA (0.40) TSHRMAPTMIFMAOBKDM4E
SCHEMBL3448041 0.72 HTR2B (0.50) TSHRMAPTKDM4ELMNATP53
SCHEMBL6266516 0.72 KDM4E (0.32) PKMTSHRKDM4E
Hydrochloric Acid SCHEMBL783467 0.71 ALDH1A1 (0.51) TSHRMAPTKDM4ELMNATP53
SCHEMBL2950618 0.71 MAPT (0.37) PKMTSHRMAPTMAOBKDM4E
SCHEMBL10921246 0.71 PKM (0.34) PKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393797-B1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM SPA (IT) 2016-04-20 EP disclosed
US-8835655-B2 Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof ZACH SYSTEM S.P.A (IT) 2014-09-16 US disclosed
US-8835655-B2 Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof ZACH SYSTEM S.P.A (IT) 2014-09-16 US disclosed
US-20120016138-A1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2012-01-19 US disclosed
US-20120016138-A1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2012-01-19 US disclosed
EP-2393797-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZaCh System S.p.A. (IT) 2011-12-14 EP disclosed
EP-2393797-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZaCh System S.p.A. (IT) 2011-12-14 EP disclosed
WO-2010089268-A3 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2010-10-14 WO disclosed
WO-2010089268-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2010-08-12 WO disclosed
WO-2010089268-A2 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZACH SYSTEM S.P.A. (IT) 2010-08-12 WO disclosed
US-7612219-B2 11—[ (Z) -3- (dimethylamino) propylidene]—6, 11-dihydro-dibenz [B,E] oxepin-2-YI ]—acetic acid URQUIMA S.A. (ES) 2009-11-03 US disclosed
US-20090005579-A1 11 - [ (Z) -3- (Dimethylamino) Propylidene] - 6, 11-Dihydro-Dibenz [B,E] Oxepin-2-Yl] - Acetic Acid URQUIMA S.A. (ES) 2009-01-01 US disclosed
EP-1881968-A2 DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS MERCKLE GMBH (DE) 2008-01-30 EP disclosed
WO-2006120010-A2 DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS MERCKLE GMBH (DE) 2006-11-16 WO disclosed
EP-0235796-B2 Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent KYOWA HAKKO KOGYO KK (JP) 1997-03-12 EP disclosed
US-5116863-A Antiallergens, antiinflammatory agents; asthma KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-05-26 US disclosed
EP-0107134-B1 TRICYCLIC ANTIDEPRESSANT DRUG IMMUNOGENS, ANTIBODIES, LABELED CONJUGATES, AND RELATED DERIVATIVES MILES LABORATORIES, INC. (US) 1986-04-09 EP disclosed
EP-0107134-A1 Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives MILES LABORATORIES, INC. (US) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005579-A1 11 - [ (Z) -3- (Dimethylamino) Propylidene] - 6, 11-Dihydro-Dibenz [B,E] Oxepin-2-Yl] - Acetic Acid OPRD1, OPRK1, MAOB PKM 1897/4885TSHR 1274/4885MAPT 3341/4885
US-20120016138-A1 PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF QDPR, OPRD1, O60361 PKM 3239/4885TSHR 3236/4885MAPT 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.